NEW AND EMERGING THERAPIES IN THE TREATMENT OF SEASONAL ALLERGIES ELLEN JETT WILSON, R.PH., PH.D. NEW AND EMERGING THERAPIES IN THE TREATMENT OF SEASONAL ALLERGIES ACTIVITY DESCRIPTION ACCREDITATION Each year millions of people suffer from the symptoms of allergic rhinitis, which includes annoying running nose, post nasal drip and watery eyes. While these symptoms are not life threatening, together they can decrease the quality of life for allergy sufferers who also experience sleep disturbances and lethargy as a result. Exciting new research in this field shows several new products in development to offer patients relief from symptoms with minimal side effects. This presentation will review traditional treatment and provide an insight on new treatments. PHARMACY TARGET AUDIENCE CE hours provided by PharmCon, Inc. meet the ANCC criteria for formally approved continuing education hours. The ACPE is listed by the AANP as an acceptable, accredited continuing education organization for applicants seeking renewal through continuing education credit. For additional information, please visit http://www.nursecredentialing.org/RenewalRequirements.aspx PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NURSING PharmCon, Inc. is approved by the California Board of Registered Nursing (Provider Number CEP 13649) and the Florida Board of Nursing (Provider Number 503515). Activities approved by the CA BRN and the FL BN are accepted by most State Boards of Nursing. The target audience for this activity is pharmacists, nurses and pharmacy technicians in hospital, community, and retail pharmacy settings. LEARNING OBJECTIVES After completing this activity, the pharmacist and nurses will be able to:     Universal Activity No.: 0798-0000-14-005-H01-P&T Credits: 1 contact hour (0.1 CEU) Review the pathophysiology and symptoms of seasonal allergies as well as list some of the causative agents of seasonal allergy Describe current non-pharmacological and pharmacological treatment strategies Identify emerging therapies for the treatment of seasonal allergies Outline the pharmacist’s role in the treatment of seasonal allergy Release Date: March 20, 2014 Expiration Date: March 10, 2017 ACTIVITY TYPE Knowledge-Based Home Study Webcast FINANCIAL SUPPORT BY Merck & Co. After completing this activity, the pharmacy technician will be able to:    List symptoms of a seasonal allergy List causes of a seasonal allergy List medications used to treat a seasonal allergy 1 ABOUT THE AUTHOR Ellen Wilson is a freelance educator based in Greenville, SC. She received a B.S. in Pharmacy and a PhD in Pharmaceutical Sciences from the University of South Carolina. Her pharmacy practice experiences include retail, hospital, and consulting pharmacy. She also has nearly ten years of collegiate teaching experience at both four-year and two-year institutions. Currently, she teaches online chemistry courses and writes pharmacy continuing education. Ellen lives in Greenville with her husband, two daughters, one cocker spaniel, and a once-stray cat. She is an active volunteer at both church and school, enjoys gardening and backyard birding, and is trying to master the art of French cooking. Ellen Jett Wilson, RPh, PhD Adjunct Professor, College of Southern Maryland FACULTY DISCLOSURE It is the policy of PharmCon, Inc. to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer of any commercial product(s) and/or service(s) discussed in an educational activity. Ellen Jett Wilson reports no actual or potential conflict of interest in relation to this activity. Peer review of the material in this CE activity was conducted to assess and resolve potential conflict of interest. Reviewers unanimously found that the activity is fair balanced and lacks commercial bias. Please Note: PharmCon, Inc. does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced and objective. Occasionally, authors may express opinions that represent their own viewpoint. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient or pharmacy management. Conclusions drawn by participants should be derived from objective analysis of scientific data presented from this monograph and other unrelated sources. 2 3 4 5 6 7 8 9 10 11 12 13 14 ACTIVITY TEST 1. What percentage of the US population is affected by seasonal allergy? A. 10% B. 25% C. 75% D. Everyone has seasonal allergies 2. Which of the following are common causative agents of seasonal allergy? A. Pollen B. Mold C. Ragweed D. All of the above 3. True or False: Dust mites, cock roaches, and pet dander are common causes of perennial allergy. A. True B. False 4. Which of the following is the recommended usage of saline nasal spray, 0.65%? A. Once daily B. 2 sprays in each nostril twice daily C. 2-6 sprays or drops in the nose as often as needed D. None of the above 5. Choose the 2nd generation antihistamines that are available over-the-counter: A. Cetirizine B. Levocetirizine C. Loratadine D. Fexofenadine E. A, C, and D—cetirizine, loratadine, and fexofenadine 15 6. Which leukotriene receptor antagonist is approved for the treatment of seasonal and perennial allergy? A. Zafirlukast B. Zileuton C. Montelukast D. All LRA are approved for allergy treatment 7. Which class of allergy treatment is considered the most effective treatment for seasonal allergy? A. Oral antihistamines B. Nasal corticosteroids C. Nasal antihistamines D. Leukotriene receptor antagonists 8. Choose the nasal corticosteroid that was made available over-the-counter in 2014. A. Budesonide (Qnasl®) B. Fluticasone (Flonase®) C. Triamcinolone (Nasacort Allergy 24HR®) D. Ciclesonide (Omnaris®) 9. Which of the following are disadvantages of subcutaneous allergy immunotherapy (SCIT)? A. Risk of systemic reaction B. Risk of fatal or near fatal reaction C. Administration in a provider’s office over a long treatment period D. All of the above 10. Which two sublingual allergy immunotherapy (SLIT) products have been recommended for approval by an FDA Advisory Panel? A. Timothy grass pollen extract B. Ragweed pollen extract C. Dust mite extract D. A and B, Timothy grass pollen extract and Ragweed pollen extract Please submit your final responses on freeCE.com. Thank you. 16